Callidus Biopharma Overview

  • Founded
  • 2010
Founded
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $15M
Latest Deal Amount

Callidus Biopharma General Information

Description

Developer of enzyme-replacement therapies for lysosomal-storage disorders. The company is focused on drug discovery, using a novel technology platform that attaches a form of the naturally occurring Insulin-like Growth Factor (IGF-2) to enhance the targeting of the therapeutic enzymes to relevant cells in the body.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Drug Delivery
Other Industries
Drug Discovery
Biotechnology
Primary Office
  • 3805 Old Easton Road
  • Doylestown, PA 18902
  • United States
+1 (215) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Callidus Biopharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 21-Nov-2013 $15M 00.000 0000 Completed Pre-Clinical Trials
1. Early Stage VC (Series A) 12-Apr-2013 00.000 00.000 000.00 Completed Pre-Clinical Trials
To view Callidus Biopharma’s complete valuation and funding history, request access »

Callidus Biopharma Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
To view Callidus Biopharma’s complete cap table history, request access »

Callidus Biopharma Executive Team (3)

Name Title Board Seat Contact Info
Paul Antony MD President, Chief Executive Officer & Board Member
Hung Do Ph.D Co-Founder, Chief Scientific Officer & Board Member
Russell Gotschall Vice President of Analytics and Assay Development
To view Callidus Biopharma’s complete executive team members history, request access »

Callidus Biopharma Board Members (3)

Name Representing Role Since
Hyuk-Jeen Suh Ph.D Self Board Member 000 0000
You’re viewing 1 of 3 board members. Get the full list »

Callidus Biopharma Former Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
WuXi Healthcare Ventures Corporate Venture Capital Minority 000 0000 000000 0
To view Callidus Biopharma’s complete investors history, request access »